Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Athira Pharma, Inc. (ATHA : NSDQ)
 
 • Company Description   
Athira Pharma Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira Pharma Inc. is based in SEATTLE.

Number of Employees: 35

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.25 Daily Weekly Monthly
20 Day Moving Average: 288,264 shares
Shares Outstanding: 37.64 (millions)
Market Capitalization: $310.50 (millions)
Beta: 3.25
52 Week High: $23.64
52 Week Low: $7.56
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -29.97% -21.12%
12 Week -11.77% -2.99%
Year To Date -36.69% -22.64%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
18706 North Creek Parkway Suite 104
-
Bothell,WA 98011
USA
ph: 425-620-8501
fax: -
ir@athira.com None
 
 • General Corporate Information   
Officers
Mark Litton - President; Chief Executive Officer and Director
Kelly A. Romano - Chairwoman of the Board of Directors
Glenna Mileson - Chief Financial Officer
Joseph Edelman - Director
James A. Johnson - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04746L104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 37.64
Most Recent Split Date: (:1)
Beta: 3.25
Market Capitalization: $310.50 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.62 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.56 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.03
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -124.00%
vs. Previous Quarter: -51.35%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -20.45
12/31/21 - -16.01
09/30/21 - -13.96
ROA
03/31/22 - -19.81
12/31/21 - -15.58
09/30/21 - -13.64
Current Ratio
03/31/22 - 28.42
12/31/21 - 28.07
09/30/21 - 25.46
Quick Ratio
03/31/22 - 28.42
12/31/21 - 28.07
09/30/21 - 25.46
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 8.02
12/31/21 - 8.60
09/30/21 - 9.02
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©